Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-LNC1016
- Development stage
- Preclinical
- Lead developer
- Yantai Lannacheng Biotechnology
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
18F-LNC1016 is an 18F-labeled diagnostic radiopharmaceutical developed by LNC Pharma for positron emission tomography (PET) imaging. It specifically targets the αvβ3 integrin (integrin alpha-V beta-3), a cell surface receptor that plays a critical role in tumor angiogenesis, progression, and metastasis. By binding to αvβ3, which is often overexpressed in lung cancer and other solid tumors, 18F-LNC1016 allows for the non-invasive visualization and quantification of integrin expression levels in vivo. This imaging capability is intended to assist in tumor detection, characterization, and the assessment of angiogenic activity to guide clinical management. The agent is currently in the preclinical stage of development for the imaging of lung cancer.
- Other names
- 18F-labeled αvβ3-targeting PET tracer
02
Targets
αVβ3 (Integrin αVβ3)
Beyond the preview
Go deeper on 18F-LNC1016.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18F-LNC1016.